Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Chapter 8 Advising Travelers With Specific Needs

Long-Term Travelers & Expatriates

Rachel B. Eidex, Anne E. McCarthy, Lin H. Chen

The risk of illness or injury increases with duration of travel, so special consideration should be given to travelers who are planning long-term visits (≥6 months is a common definition) to low- or middle-income countries. Points to discuss in the pre-travel consultation include accessing care at the destination, vaccines, infectious diseases not prevented by vaccines, injury, and psychological issues that long-term travelers may encounter.


Before departure, all long-term travelers should undergo an extensive medical and dental examination. Travelers should anticipate that they will need care at some point during their stay, and they should plan where they will get it and how they will pay for it. Those traveling for work or with an organization (such as a university or the Peace Corps) may have a predetermined source of care; other travelers should identify a source in advance (see Chapter 2, Obtaining Health Care Abroad for the Ill Traveler). Long-term travelers should also determine if they will need supplemental travel health insurance and evacuation insurance (see Chapter 2, Travel Insurance, Travel Health Insurance, & Medical Evacuation Insurance).

In some countries, travelers are likely to encounter counterfeit or low-quality medications. Because the pills and packaging may be nearly indistinguishable from their legitimate counterparts, travelers should consider bringing a supply of their routine medications (antihypertensive or antihyperlipidemic drugs, for example) from the United States (see Chapter 2, Perspectives: Pharmaceutical Quality & Counterfeit Drugs).


Routine vaccines, including influenza vaccine, should be updated. In addition, long-term travelers should be aware of any vaccine requirements at their destination, either for employment, schooling, or entry. A number of travel-related vaccines warrant consideration:

  • Hepatitis A and typhoid vaccines are appropriate given the cumulative risk, although the traveler should be aware that the latter does not provide full protection.
  • Travel-associated hepatitis B infections are rare, but the risk for travelers may be higher than for nontravelers, and the vaccine should be considered for all long-term travelers and expatriates.
  • Meningococcal disease is more likely in travelers with prolonged exposure to local populations in endemic or epidemic areas; quadrivalent vaccine should be considered for those at risk.
  • According to the Advisory Committee on Immunization Practices recommendations, Japanese encephalitis vaccine is recommended for people living in endemic areas. It is also recommended for travelers who plan to stay ≥1 month during the virus transmission season (see Chapter 3, Japanese Encephalitis).
  • Rabies preexposure immunoprophylaxis is an important consideration for people spending a prolonged time in endemic countries, especially in areas where rabies immune globulin is not available. Vaccinating children who will be living in high-risk areas is a priority.
  • Yellow fever vaccine should be considered for travelers who will be staying in an endemic area or a country with a vaccine requirement, or who may be traveling to one.

In addition to the intended destination, consider disease risk in surrounding areas, since long-term travelers may be likely to travel locally. For example, a short-term traveler to Seoul would not be considered at risk for Japanese encephalitis, but an expatriate living in Seoul may have opportunities to visit the Korean countryside or other areas in Asia where he or she could be exposed.



Data suggest that the incidence of malaria increases and the use of preventive measures decreases with increasing length of stay. For instance, malaria incidence in British travelers returning from West Africa after a stay of 6–12 months was 80 times that of the incidence in travelers who had stayed only 1 week. Expatriates working with the International Committee of the Red Cross who stayed for a mean of 11 months in sub-Saharan Africa were diagnosed with malaria at a rate of 3.81 cases per 1,000 person-months of stay. Expatriate corporate employees in Ghana reported that adherence to malaria chemoprophylaxis deteriorated with increasing duration of stay, and all those who had been on the site for >1 year had abandoned chemoprophylaxis. About half of the cohort used insect repellent only intermittently, and more than one-third never used repellent. Another expatriate cohort living in Nigeria revealed similarly low adherence to chemoprophylaxis; analysis of pharmacy records and household interviews found that only 39% of households were adherent. Given the high relative risk of malaria for travelers in Africa, these data on long-term travelers and expatriates highlight worrisome risks and practices.

A traveler who will be residing in an area of continuous malaria transmission should continue to use malaria chemoprophylaxis for his or her entire stay. It is important to reassure the traveler that the drugs are safe and effective. Doxycycline has been well-tolerated for long-term malaria chemoprophylaxis in the military, and CDC has no recommended limits on its duration of use for malaria chemoprophylaxis. Mefloquine has been well-tolerated during prolonged stays by Peace Corps volunteers, with a discontinuation rate of 0.9%, and showed no evidence of accumulation after long-term use; therefore, mefloquine may be appropriate for long-term chemoprophylaxis for most chloroquine-resistant areas because of its convenient weekly dosing. Atovaquone-proguanil has shown good long-term tolerability in postmarketing surveillance, with a discontinuation rate of only 1% because of diarrhea. Primaquine (in people without glucose-6-phosphate dehydrogenase [G6PD] deficiency) has been well-tolerated as long-term primary prophylaxis in Japanese transmigrants to Papua New Guinea. A potential concern with chloroquine is retinal toxicity when a cumulative dose of 100 g is reached, which may occur after 5–6 years of weekly dosing. A baseline ophthalmologic examination is recommended, with follow-up every 6–12 months after 5 years of use. Except for ophthalmologic evaluation when taking chloroquine long-term, no specific testing is recommended for the long-term use of other antimalarial drugs.

A consideration for long-term female travelers to malarious areas is pregnancy (see the Pregnant Travelers section earlier in this chapter). Malaria infection during pregnancy can result in potentially severe complications to both mother and fetus. When pregnancy is anticipated, chemoprophylaxis options may need to be adjusted. Ideally, this possibility should be explored before travel with all female long-term travelers of childbearing age. For women who are pregnant or plan to become pregnant during long-term travel, mefloquine is considered safe in all trimesters. Data from published studies in pregnant women have shown no increase in the risk of teratogenic effects or adverse pregnancy outcomes after mefloquine prophylaxis during pregnancy. Chloroquine has also been used long-term without ill effect on pregnancy. If a woman traveling long-term is taking atovaquone-proguanil, doxycycline, or primaquine, she should discontinue her medication and begin weekly mefloquine (or chloroquine in those areas where it remains efficacious) and wait at least 5–6 weeks to conceive so that a therapeutic level of mefloquine can build up in the blood.

Women who become pregnant while taking antimalarial drugs do not need a therapeutic abortion but should be advised during the pre-travel consultation of potential risks. The effect of atovaquone-proguanil on the fetus is unknown, but doxycycline is associated with fetal toxicity in animals and is contraindicated in pregnant women. Primaquine may harm a G6PD-deficient fetus, so it should not be used in pregnancy.

For long-term travelers, also stress the need for adjuncts to chemoprophylaxis, such as personal protection measures to avoid mosquito bites (such as sleeping under a bed net and using screens). Travelers should bring a sufficient supply of antimalarial drugs from the United States, since drugs purchased at the destination may be of poor quality or counterfeit. Even with urging to adhere to personal protective measures and reassurance that long-term chemoprophylaxis is safe and effective, adherence is likely to decline over time. Consequently, the pre-travel consultation for a long-term traveler to a malarious area should stress the severity of malaria, its signs and symptoms, and the need to seek care immediately if they develop. Travelers could consider bringing a reliable supply of drugs to treat malaria if they are diagnosed with malaria. For additional discussion, see the next section in this chapter, Perspectives: Malaria in Long-Term Travelers & Expatriates.

Other Diseases

Because diarrhea and gastrointestinal diseases are common in long-term travelers, they should be educated about the management of acute diarrhea, including rehydration, the use of antimotility agents, empiric antimicrobial therapy, and when to seek care.

HIV and sexually transmitted disease risks are increased in travelers and expatriates, and the consistent use of condoms in expatriates is low (approximately 20%). Long-term travelers should be educated about the risk of HIV and sexually transmitted diseases in their destination, as well as preventive measures. The potential for occupational exposure to HIV is important to consider in health care workers; postexposure prophylaxis with highly active antiretroviral therapy and risk avoidance should be included in the pre-travel consultation (see Chapter 2, Occupational Exposure to HIV).

Transfusion is a potential source of hepatitis C infection in expatriates. The risk of hepatitis E, spread by the fecal-oral route, is highest in Asia, although it has been transmitted in many different tropical locations. Pregnant women are at highest risk of fulminant disease.

Other infections vary with location and include schistosomiasis, which may be prevented by not swimming or wading in fresh water. Again, this risk is difficult to communicate to long-term travelers who, for example, may be living in sub-Saharan Africa and who look forward to their vacation at Lake Malawi. The risks of schistosomiasis and screening on return should be discussed. Tuberculosis risk may rise to the level of the local population if the traveler or expatriate has a longer stay and intimate contact with the local population. A baseline tuberculin test and the same test following travel should be considered.


Injuries are the leading cause of preventable death in travelers, so long-term travelers should be educated about safety. Road and vehicle safety should be stressed, and travelers should choose the safest vehicle options available. Roads are often poorly constructed and maintained, traffic laws may not be enforced, vehicles may not have seatbelts or be properly maintained, and drivers may be reckless and poorly trained. See Chapter 2, Injuries & Safety, for strategies to reduce the risk of traffic and other injuries.


The stress of long-term travel can trigger or exacerbate psychiatric reactions. A long-term traveler should be assessed for preexisting psychiatric diagnosis, depressed mood, recent major life stressors, and use of medications that may have psychiatric effects. These conditions may suggest a need for further screening. All long-term travelers should be urged to take care of their physical and mental health by exercising regularly and eating healthfully. They should be able to recognize signs of anxiety and depression and have a plan for coping with them. Having photographs or other mementoes of friends and family at hand and staying in close contact with loved ones at home can alleviate the stress of long-term travel. For more information, see Chapter 2, Mental Health & Travel.


  1. Arguin PM, Krebs JW, Mandel E, Guzi T, Childs JE. Survey of rabies preexposure and postexposure prophylaxis among missionary personnel stationed outside the United States. J Travel Med. 2000 Jan;7(1):10–4.
  2. Banta JE, Jungblut E. Health problems encountered by the Peace Corps overseas. Am J Public Health Nations Health. 1966 Dec;56(12):2121–5.
  3. Berg J, Visser LG. Expatriate chemoprophylaxis use and compliance: past, present and future from an occupational health perspective. J Travel Med. 2007 Sep–Oct;14(5):357–8.
  4. Chen LH, Wilson ME, Davis X, Loutan L, Schwartz E, Keystone J, et al. Illness in long-term travelers visiting GeoSentinel clinics. Emerg Infect Dis. 2009 Nov;15(11):1773–82.
  5. Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA. 2006 Nov 8;296(18):2234–44.
  6. Cobelens FG, van Deutekom H, Draayer-Jansen IW, Schepp-Beelen AC, van Gerven PJ, van Kessel RP, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet. 2000 Aug 5;356(9228):461–5.
  7. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med. 2005 Apr;2(4):e100.
  8. Correia JD, Shafer RT, Patel V, Kain KC, Tessier D, MacPherson D, et al. Blood and body fluid exposure as a health risk for international travelers. J Travel Med. 2001 Sep–Oct;8(5):263–6.
  9. Freeman RJ, Mancuso JD, Riddle MS, Keep LW. Systematic review and meta-analysis of TST conversion risk in deployed military and long-term civilian travelers. J Travel Med. 2010 Jul;17(4):233–42.
  10. Guse CE, Cortes LM, Hargarten SW, Hennes HM. Fatal injuries of US citizens abroad. J Travel Med. 2007 Sep–Oct;14(5):279–87.
  11. Hillel O, Potasman I. Correlation between adherence to precautions issued by the WHO and diarrhea among long-term travelers to India. J Travel Med. 2005 Sep–Oct;12(5):243–7.
  12. Leutscher PD, Bagley SW. Health-related challenges in United States Peace Corps volunteers serving for two years in Madagascar. J Travel Med. 2003 Sep–Oct;10(5):263–7.
  13. MacPherson DW, Gushulak BD, Sandhu J. Death and international travel—the Canadian experience: 1996 to 2004. J Travel Med. 2007 Mar–Apr;14(2):77–84.
  14. Pandey P, Shlim DR, Cave W, Springer MF. Risk of possible exposure to rabies among tourists and foreign residents in Nepal. J Travel Med. 2002 May–Jun;9(3):127–31.
  15. Patel D, Easmon CJ, Dow C, Snashall DC, Seed PT. Medical repatriation of British diplomats resident overseas. J Travel Med. 2000 Mar–Apr;7(2):64–9.
  16. Toovey S, Moerman F, van Gompel A. Special infectious disease risks of expatriates and long-term travelers in tropical countries. Part I: malaria. J Travel Med. 2007 Jan–Feb;14(1):42–9.
  17. Toovey S, Moerman F, van Gompel A. Special infectious disease risks of expatriates and long-term travelers in tropical countries. Part II: infections other than malaria. J Travel Med. 2007 Jan–Feb;14(1):50–60.